Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials

J Thorac Dis. 2013 Aug;5(4):383-4. doi: 10.3978/j.issn.2072-1439.2013.07.32.

Authors

Antonio Passaro¹, Bruno Gori, Filippo de Marinis

Affiliation

¹ 1 Oncological Pulmonary Unit, San Camillo, High Specialization Hospital, Rome, Italy.

PMID: 23991291
PMCID: PMC3755655
DOI: 10.3978/j.issn.2072-1439.2013.07.32

No abstract available

Keywords: Non-small-cell lung cancer (NSCLC); afatinib; epithelial growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI).